Dr. Chaudhry on DRd Triplet in Transplant-Ineligible Multiple Myeloma

Video

In Partnership With:

Maria Chaudhry, MBBS, discusses the use of daratumumab (Darzalex), lenalidomide (Revlimid), and dexamethasone in transplant-ineligible patients with multiple myeloma.

Maria Chaudhry, MBBS, a hematologist at The Ohio State University Comprehensive Cancer Center—James, discusses the use of daratumumab (Darzalex), lenalidomide (Revlimid), and dexamethasone (DRd) in transplant-ineligible patients with multiple myeloma.

In the phase III MAIA trial, transplant-ineligible patients were randomized to receive DRd or the combination of lenalidomide and dexamethasone alone until progression. Approximately 44% of patients were 75 years of age or older.

The addition of daratumumab resulted in a 44% reduction in the risk of progression or death versus the combination alone, says Chaudhry. Moreover, the overall response rate (ORR) with daratumumab was also better, at 93%. Data from the trial served as the basis for the regimen’s approval in June 2019.

In terms of adverse events, the incidence of grade ≥3 neutropenia was higher in the daratumumab arm, concludes Chaudhry.

Related Videos
Mike Lattanzi, MD, medical oncologist, Texas Oncology
Vikram M. Narayan, MD, assistant professor, Department of Urology, Emory University School of Medicine, Winship Cancer Institute; director, Urologic Oncology, Grady Memorial Hospital
Stephen V. Liu, MD
S. Vincent Rajkumar, MD
Pashtoon Murtaza Kasi, MD, MS
Naseema Gangat, MBBS
Samilia Obeng-Gyasi, MD, MPH,
Kian-Huat Lim, MD, PhD
Saurabh Dahiya, MD, FACP, associate professor, medicine (blood and marrow transplantation and cellular therapy), Stanford University School of Medicine, clinical director, Cancer Cell Therapy, Stanford BMT and Cell Therapy Division
Muhamed Baljevic, MD